CD8A and autoimmune glomerulonephritis: However, an anti-CD8 monoclonal antibody therapy was effective in both the prevention and treatment of experimental autoimmune glomerulonephritis [29], which could be associated with the effects of CD8+ cells on ICAM-1 and cytokine expression in crescentic glomerulonephritis [30].